# curasight

Curasight is on mission to improve the lives of millions of people with cancer

Økonomisk Ugebrev – 31 May 2023



#### **Forward-looking Statements**

This presentation contains forward-looking statements that provide Curasight's expectations or forecasts of future events such as

- new product developments,
- regulatory approvals and
- financial performance.

These forward-looking statements are based on management's reasonable expectations and assumptions as of the date of this document regarding important risk factors.

Such forward-looking statements are subject to risks, uncertainties and may be impacted by inaccurate assumptions. Actual performance and financial results may differ materially from projections and estimates expressed in the forward-looking statements because of many factors. Curasight undertakes no obligation to update forward-looking statements.



IMPROVING CANCER TREATMENTS WITH ACCURATE DIAGNOSIS & MORE GENTLE, TARGETED THERAPY Pioneering intelligent cancer imaging and more gentle and efficient treatment of solid tumors using nuclear medicine

Main focus brain and prostate cancer

Cutting edge uPAR Theranostics platform: Two-pronged approach combines diagnosis via uTRACE and treatment via uTREAT

Industry experienced leadership team with extensive skills in science, business and commercialisation

2

Global nuclear medicine market is expected to grow from \$5.9 Billion in 2019 to \$35 Billion in 2031\*



Strategy to develop products and get them to the market through strategic partnering – cash runway to H1 2024



# In May 2023 Curasight and Curium announce global partnership for uTRACE<sup>®</sup> in prostate cancer

- Curasight to develop its proprietary uTRACE<sup>®</sup> PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for manufacturing and commercialization
- Curasight eligible for up to USD 70 mn in development and commercial milestones as well as double-digit royalties on sales on eventual commercialization
- The agreement supports Curasight's strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer



CLIPAC	
(Jurds	

Press release May 1, 2023

Curasight and Curium announce global partnership for uTRACE<sup>®</sup> in prostate cancer

 Consight to develop its proprietary uTRACE<sup>®</sup> PET imaging technology to obtain regulatory approval in EU and USA, with Culture responsible for manufacturing and commercialization

revel in EU and USA, with Culturn responsible for manufacturing and commercialization asight eligible for up to USD 70 mn in development and commercialization ble-digit royables on sales on eventual commercialization

double-right royables on sales on eventnal commercialization The agreement supports Corasipht's strategy to leverage partnerships as it progresses its uBNR theraneodic solution to indeprise and treat certain types of cancer

penhager, Dennark, May 1, 2023 – Curasight A/S ("Curasight" or "the Company" – TCRER CURAC) nonunced today that it has entered into an exclusion global licence and collaboration agreement with nium inc. – a global leader in radiopharmaceuticali – for the development and corresercialization of RAC? for use inpostance curace.

ther the terms of the appresent, Consulpt will develop its propertury, VTMCC<sup>1</sup> exchanges for our is obtain career with impairture, approval is granted in the EQ and UAA. Comme will have range-miniting the commercial manufacture of uTRACE<sup>2</sup> and workly-kide commercialization. Cursight is eligible to color up to USD 70 mm in development and commercial relations as well as double-digit percentage willing on salar implementation percentage method commercialization.


ranging any iso position of TARCE\* as a first-in-cluss EFE traces that can ensure as an alternative or planment to traditional lengths of the evolution of particults with protote cancer in active millions. Cancing the county received without from the US to do and Sing Administration (FOA) in a eND meeting about the development plan for the "Cu-labeled version of aTRACE for use in prostate non.

In a set first of sign the partnership with Corken, which we believe provide further salisation of some SACE "partners well is use in provide access. One collaboration partners to counselfs's shareful in the solarization of USACE" and Corken's provide respective, and global trade stated in the matchaning and conversionation of indicated memory counsels of shareful to could be the partnership supports both deviapment of our disposition global trade is under to fulfilling actions of the counsels with the state of our disposition global trade of the salisation. The partnership supports both deviapment of our disposition global trade of the salisation.

b) the global isolate in nuclear medicen, Curran to desilutate to developing the averag diagnostic and taments obtained on score patients. We are excluded does the opportunity to develop regard our networks of popul-of labeland HT for diagnostic franchism is a premising inductions. Our partnerships with energy control provide the state of the bing this intervative isolation to the state and baselinear professionals among the variet Added bing this intervative isolation to global energy of baselinear professionals among the variet Added antiming Tablesian, Calmo Table MAD difference and labelinear professionals among the variet Added professional and the state of the sta

The uRMACL particles is part of Consights of MI descends arbitrar, make up of its URMACL despetite tabology and its URMACL despetite tabology and its URMACL despetite tabology and its URMACL approximation tabology and its URMACL approximation tabology and its URMACL approximation to provide a more accurate approach is certain type of comer including protect accuracy, which campoint a particular tabolic transmission of the set of the URMACL approximation to provide a more accurate tabolic transmission. The technology has been tenden in multiple Phase 2 direct transmission. Curvaget and keep all rights to develop and commercials and PACL<sup>®</sup> in Indications confide protestacences.





# curasight

# Working for Better Diagnosis and Treatment of Cancer

- Late-stage clinical company
  - founded in Copenhagen, Denmark 2013, based on >10 yrs academic research (Rigshospitalet)
  - More than EUR 20 M raised to date, cash runway to H1 2024
- > Leveraging understanding of uPAR in both diagnosis and treatment
  - Imaging platform uTRACE<sup>®</sup> led to creation of uTREAT<sup>®</sup> platform for more gentle and targeted treatment
  - Focus on brain and prostate plus multiple other potential cancer types
- Safe and well-tolerated
  - uTRACE<sup>®</sup> broadly tested > 8 phase II clinical trials and > 400 patients
  - Studies in prostate cancer, Head and Neck cancer and Neuroendocrine tumors (NET)
- > Exciting commercial potential
  - Rapidly growing market estimated to be \$35 Billion in 2031
  - Strong IP position with issued patents both in the US, EU, CAD, and JPN

# **Growing Nuclear Medicine Market Worldwide**


#### **Growth factors**

- Aging population, increase number of cancer
- Wider use of nuclear medicine around the would
- Introduction of new radiopharmaceuticals

#### From 2021 to 2031

- Total Nuclear Medicine sales grow 19% per year
- Nuclear Medicine Therapy grows 35% per year
- Nuclear Medicine Diagnostics grows 7% per year

#### Global nuclear medicine market expected to grow from \$5.9 Billion in 2019 to \$35 Billion in 2031



MEDraysintell Nuclear Medicine Report & Directory, 2022 edition




#### Using our uPAR Theranostics, Platform to Create a, Strong Pipeline





# The Theranostic principle








#### Tackling the Need for More Gentle and Targeted Treatment

- Over 50% of solid tumor cancer patients receive external radiation therapy.
- Traditional radiation therapy also harms healthy tissue.
- Our uPAR Theranostics platform is more targeted and offers a more tailored and gentle personal cancer therapy.



# **Our Cutting-Edge Theranostics Platform**

Our **uPAR Platform** targets a clinically validated biomarker - uPAR - for both diagnosis and treatment *providing* 

- non-invasive PET imaging for diagnosis
- targeted radionuclide therapy for treatment

#### (Diagnostics) uTRACE®

uPAR PET imaging with uTRACE®

- improved cancer diagnosis
- across several cancer types

#### (Therapy) uTREAT®

uPAR targeted radionuclide therapy

- uPAR-positive cancers
- pre-clinical validatation in place




#### **uPAR Theranostic**

# **Targeting uPAR – a Validated Biomarker**

For both diagnoses and treatment, the patient is injected with a compound that targets uPAR.

- uPAR is expressed in cancer cells <u>not</u> in normal tissue and shown across most cancer forms
- High expression of uPAR correlates with invasive/aggressive cancer and needs treatment.
- uPAR is cancer specific but not cancer type specific.





を1型 BRAIN CANCER

#### **Glioblastoma – need for better therapy**

- Most common primary malignant brain tumor
- 65,000 new cases of brain cancer each year in the US and EU of which 30,000 are high grade gliomas
- > 10% of these cases are in children
- Radiation therapy is standard of care for most patients
- Combined with chemotherapy (temozolomide)
- Median survival: 14 months
- 5-year survival: 5%
- Almost no improvement in therapy over last decades








 $(\mathbb{P})$ 

**BRAIN CANCER** 


#### **uPAR-PET in glioblastoma patients**




# "What you see - is what you treat"



# uTREAT<sup>®</sup> - Treatment Advantages Using Targeted Radiotherapy





**Today – Conventional Radiotherapy** 


**Tomorrow - uTREAT®** 





#### **Prostate cancer program**

- Prostatectomies
  - most are unnecessary
  - *impotence experienced in 70% of all patients after prostatectomy*
- "The major problem is how to recognize those tumors that do not need radical prostatectomy" (From Guidelines on Prostate Cancer, Eur. Assoc. of Urology 2013)








PROSTATE CANCER


#### **Challenges in diagnosing prostate cancer**








# First uPAR-PET of Prostate cancer patient (uTRACE)



Persson M, Skovgaard D et al. Theranostics 2015 (<sup>64</sup>Cu-DOTA-AE105)








#### NEUROENDOCRINE TUMOURS

#### Neuroendocrine tumors – need for better diagnosing and therapy

- NET are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body.
- Each year approximately 35,000 new cases are diagnosed in the US and EU.
- Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU.
- The global market for NET cancer is expected in 2027 to have a value of USD 2.3 billion
- Radiation therapy is standard of care for most patients combined with surgery and chemotherapy









NEUROENDOCRINE TUMOURS

### **Outcome of the Neuroendocrine Tumor study - uTRACE®**

#### Conclusion

- NET of all grades are uPAR positive
- uTRACE<sup>®</sup> strongly prognostic
- Demonstrates that NET may be target for uTREAT<sup>®</sup>







**HEAD & NECK CANCER** 

#### Head and Neck cancer – need for better diagnosing and therapy

- Head and Neck cancer is the term used to describe a variety of malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth
- The annual incidence of head and neck cancers worldwide is more than 550,000 cases each year
- 115,000 new cases of Head and Neck cancer each year in the US and EU
- Radiation therapy is standard of care for most patients combined with surgery and chemotherapy








HEAD & NECK CANCER

#### **Outcome of the Head and Neck Cancer study - uTRACE®**

#### Conclusion

- uTRACE<sup>®</sup> strongly prognostic
- Beats FDG-PET, TNM stage and p16 status regarding relapse-free survival
- uTRACE<sup>®</sup> could become valuable for identifying patients suited for de-escalation of treatment and risk stratified follow-up schemes
- Demonstrates that Head and Neck cancer may be target for uTREAT<sup>®</sup>



# 2023 Milestones

**Overview of news flow and important milestones for Curasight 2023** 

Planned	Event type	Product	Details
H1 2023	Trial completed	uTRACE®	Results of phase IIb study <sup>*)</sup> in Glioblastoma
H1 2023	Study completed	uTREAT®	Results of preclinical study in Glioblastoma
H2 2023	Study completed	uTREAT®	Results of preclinical study in additional cancer type
H2 2023	Regulatory	uTRACE®	Clinical trial application for Prostate cancer (EU)
H2 2023	Regulatory	uTRACE®	Investigational new drug application for Prostate cancer (US)
			*) Investigator initiated study



#### **SEB commissioned research**

- Potential for both uTRACE & uTREAT in new indications "We believe Curasight will be most successful in providing an option for treating aggressive metastatic cancer that cannot be treated with surgery, especially within the new indications"
- "Our analysis shows that the value of Curasight can increase significantly on the back of clinical success. Our valuation range is DKK 45 63 (EUR 6 8.5) per share with a weighted mid-point SOTP value of DKK 54 (EUR 7.2) per share."
- This represents a **potential upside** of approximately **x2** compared to current share price of 25 (24 May 2023)

	nt					в			
TO BLUE TRUE IN ON	TAUNOR DESIGN CITE INTO THE OWING WORD IS SMANING.		AN ADDRESS OF IN	ww.prvs#					
	Company Update	Healthcare	Does	nark	76.87	r 2021			
	Trace it.	treatit							
_	Curesight is a	Danish biotect	company with	two core radi	opharmac	euticel	_		
	Corporate Resear	ch							
y Data (20216) a (DR) arts	Curasight SEB								
fet ep(340n) fet ep(350n)	NOT TO BE DISTRIBUTED IN OR TA JUNEEDICTION WHERE TO DO SO W	KEN OR TRANSPORTS DULD BE UNLAWFUL	DINTO, THE LIMITED O	PATES CANADA, M	PAR AUTO	LIA OE IN AN	OTHER		
Act op (1000) Act op (1000) Cold (0000) Cold (0000) Cold (0000)		Con	npany tipdate	Healthcare		Denmé	ń	29.0	ctober 2022
entity (E) (dig setter (n)			More is m	ore					
no Price (12H)	Applicity Water (JSS) is per above.   Statistics Constant Statistics Constant Statistics   Statistics Constant Statistics Constatistics   Stat							his reason, olue of the soumptions in the new and try to or treating especially in peptide soundscrime incurs nome	
			We update our	valuation rang h a mid-point	e from DKI value of D	KK 54. W	nid-point 1 v use a bo make gus	ttom-up /	NPV-SOTP sumptions
intenting commu minissioned by: resignt	-		based on simil clinical trials.	e at our mid-p ar treatment o	options, co	mpany in	formation		Sinical and
riteting commu mmissioned by	Share Price (12H)		analysis to arm based on simil clinical trials. Financials (DKK	ar treatment o	options, co				
rkoting commi minissioned by resight	Share Price (12H)		analysis to arriv based on simili clinical trials.	ar treatment o	options, co	2021 0 (8) (9) (0.41) (0.15) 0.00	20228 0 (37) (186) (186) 0.00	2023M 0 (17) (180) (1.86) 0.00	2024E 0 (53) (53) (53) (53) (2.66) (2.66) 0.00
rkoting commi minissioned by resight	An	unantity.	onalysis to arm based on simil- clinical trade. Financials (DKK Year and Dec Rowmans(m) Ad ERT Process profit (m) EPS Ad EPS DPS Rowman growth ( Ad ERT growth (	n troatment (	2025 0 (4) (5) (5,32) (5,32)	2021 0 (8) (9) (0.41) (0.15)	0 (17) (17) (18) (186)	20234 0 (17) (17) (184) (1.86)	2024E 0 (53) (53) (2.6) (2.6)
rkoting commi minissioned by resight	Anton guer ( Server to General to	Aug On	onalysis to anni based on simil clinical trials. Financials (DKK Year end: Dec Rovemant (m) Ad; BIT Pro-tax profit (m) Pro-tax profit (m) Pro-tax profit (m) DPS Ad; DPS DPS Rovemant proch (*	ar treatment o	2029 0 (4) (5) (5,32) (5,32) 0,00 n.m. n.m.	2021 0 (8) (9) (0.41) (0.15) 0.00 5.00 5.00	2002H (17) (17) (186) (186) 0.00 5.%	20238 0 (37) (180) (1.86) 0.00 m.	20248 0 (53) (53) (246) (246) (246) 0.00 5.05 5.05 5.05 5.05 5.05 5.05 5.0
riteting commu mmissioned by	1 Anno	Aug On	onalysis to arms bacod on simil clinical trials. Financials (DKK Faransis (n) Ad; URT Pro-tas prot (n) Pro-tas prot (n) DS Exercus growth ( Ad; URT prosth) Ad; URT prosth) Ad; URT prosth) Ad; URT prosth) Ad; URT prosth)	n) n) n) n) n) n) n) n) n) n)	2000 0 (4) (5) (5) 000 5.5. 5	2021 0 (8) (0 41) (0 15) 0.00 5.05	20021E 0 (17) (130) (136) 0.00 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.6	20230 0 (17) (186) (186) 0.00 n.m. n.m. n.m. n.m. 0.m. (849)	20248 0 (53) (53) (2.65) (2.65) (2.65) 0.00 5.65 0.00 5.65 0.00 5.65 0.00 5.65 0.00 5.65 0.00 5.65 0.00 5.55 5.55 0.00 5.55 0 5.55 0.00 5.55 0 0 5.55 0 5.55 0 5 0

#### Link to SEB



# **Contact information**



Ulrich Krasilnikoff CEO/CFO & Co-owner uk@curasight.com



**Prof. Andreas Kjaer,** *CMO/CSO & Co-founder*